Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferranem Microgránulos is an oral iron supplement containing iron(III) hydroxide polymaltose complex (IPC). Developed and marketed by the Chilean pharmaceutical company Chemopharma, it is indicated for the prevention and treatment of iron deficiency and iron deficiency anemia. The IPC formulation consists of a polynuclear iron(III)-hydroxide core surrounded by polymaltose molecules, which protects the iron from causing oxidative damage in the gastrointestinal tract and allows for controlled absorption via active transport. This results in improved tolerability and a lower incidence of gastrointestinal side effects compared to traditional ferrous salts. The microgranule formulation is specifically designed to provide flexible dosing and ease of administration for patients who may have difficulty with traditional tablet forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron polymaltose complex.